Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 6, 2006, Pages 764-769

  Kato, Mikio ^a   Sada, Toshio ^a   Chuma, Hiroko ^a   Mizuno, Makoto ^a   Terashima, Hideki ^a   Fukushima, Yasuo ^a   Koike, Hiroyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Antiatherosclerotic effect; ApoE deficient mice; AT1 receptor blocker; Plasma cholesterol level

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; OLMESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEEDING; HUMAN; HYPERLIPIDEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; AORTIC VALVE; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; HEART RATE; HYPERLIPIDEMIAS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; TETRAZOLES; TRIGLYCERIDES;

EID: 33748116908     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211788.37658.ad     Document Type: Article

References (28)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
3. Walsh MN, Simpson RJ Jr, Wan GJ, et al. Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. Am J Manage Care. 2002;8:937-946.
4. Chobanian AV, Haudenschild CC, Nickerson C, et al. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
5. Sugano M, Makino N, Yanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis. 1996;127:123-129.
6. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol. 1999;128:523-529.
7. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999;12:28-34.
8. Kato M, Sada T, Mizuno M, et al. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits. J Cardiovasc Pharmacol. 2005;46:556-562.
9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Eng J Med. 1992;327:669-677.
10. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD): rationale design, and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
11. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
12. Ferrario CM, Smith R, Levy P, et al. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci. 2002;323:17-24.
13. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41:515-527.
14. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93:65-77.
15. Keidar S, Kaplan M, Hoffman A, et al. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis. 1995;115:201-215.
16. Keidar S, Heinrich R, Kaplan M, et al. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol. 2001;21:1464-1469.
17. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997;95:473-478.
18. Daugherty A, Rateri DL, Lu H, et al. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 2004;110:3849-3857.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
20. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80mg and pravastatin 40mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644-1648.
21. Raal FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000;150:421-428.
22. Kobayashi T, Matsumoto T, Kamata K. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol. 2000;131:231-238.
23. Horiuchi M, Cui TX, Li Z, et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation. 2003;107:106-112.
24. Li Z, Iwai M, Wu L, et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension. 2004;44:758-763.
25. Chen J, Li D, Schaefer RF, et al. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol. 2004;44:446-452.
26. Nishikawa H, Miura S, Shimomura H, et al. Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis. J Cardiol. 2005;45:107-113.
27. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687-3692.
28. Fliser D, Buchholz K, Haller H. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107.